Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-3Q in Perianal Fistulizing Crohn's Disease
NCT06918808Phase 2Recruiting
- Sponsor
- Direct Biologics
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bone marrow mesenchymal stem cell derived extracellular vesicles in Crohn's disease (6 arms), sponsored by Direct Biologics. Primary endpoint: Combined Remission at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06918808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918808.